Ozempic sparked the weight-loss drug trend. Mounjaro is leading it in India
Six months after launch, Eli Lilly’s Mounjaro is already India’s second-biggest pharma brand, ahead of antacid Pan and just behind antibiotic Augmentin. Days later, Eli Lilly announced a $1 billion investment and a new Hyderabad hub. The timing is no accident: India has one of the world’s largest obese and diabetic…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Daybreak
See all episodes →
Similar episodes from other shows
More like Daybreak →
Weight Loss Just Got Easier in India?
Semaglutide Goes Generic: Big Pharma’s Moat Breaks
Can India become the pharmacy for weight-loss drugs?
Mounjaro hits India, Bengal's Diamond Harbour Model, and Waqf Bill faces heat
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.